Registries in rheumatoid arthritis and autoimmune diseases: data from the French registries.
about
Biologic and oral disease-modifying antirheumatic drug monotherapy in rheumatoid arthritisBiologics registers in RA: methodological aspects, current role and future applications.Safety of surgery after rituximab therapy in 133 patients with rheumatoid arthritis: data from the autoimmunity and rituximab registry.Factors associated with withdrawal of the anti-TNFα biologics in the treatment of rheumatic diseases: data from the Hong Kong Biologics Registry.Safety of biologics in rheumatoid arthritis: data from randomized controlled trials and registries.Effectiveness of biologic DMARDs in monotherapy versus in combination with synthetic DMARDs in rheumatoid arthritis: data from the Swiss Clinical Quality Management Registry.Late-onset neutropenia after treatment with rituximab for rheumatoid arthritis and other autoimmune diseases: data from the AutoImmunity and Rituximab registry.Safety of surgery in patients with rheumatoid arthritis treated by abatacept: data from the French Orencia in Rheumatoid Arthritis Registry.Long-Term Maintenance of Certolizumab Pegol Safety and Efficacy, in Combination with Methotrexate and as Monotherapy, in Rheumatoid Arthritis Patients.Risk of Tuberculosis Reactivation in Patients with Rheumatoid Arthritis, Ankylosing Spondylitis, and Psoriatic Arthritis Receiving Non-Anti-TNF-Targeted BiologicsClinical and radiographic outcomes at 2 years and the effect of tocilizumab discontinuation following sustained remission in the second and third year of the ACT-RAY study.Using epidemiological registry data to provide background rates as context for adverse events in a rheumatoid arthritis drug development program: a coordinated approach.Abatacept monotherapy compared with abatacept plus disease-modifying anti-rheumatic drugs in rheumatoid arthritis patients: data from the ORA registry.Efficacy of biological agents administered as monotherapy in rheumatoid arthritis: a Bayesian mixed-treatment comparison analysis.Long term treatment with abatacept or tocilizumab does not increase Epstein-Barr virus load in patients with rheumatoid arthritis - A three years retrospective studyComparison of serological methods with PCR-based methods for the diagnosis of community-acquired pneumonia caused by atypical bacteria.Analysis and Breakdown of Overall 1-Year Costs Relative to Inpatient and Outpatient Care Among Rheumatoid Arthritis Patients Treated with Biotherapies Using Health Insurance Claims Database in Alsace.Characteristics Associated with Biologic Monotherapy Use in Biologic-Naive Patients with Rheumatoid Arthritis in a US Registry Population.Incidence density of serious infection, opportunistic infection, and tuberculosis associated with biologic treatment in patients with rheumatoid arthritis - a systematic evaluation of the literature.Real-world effectiveness of abatacept for rheumatoid arthritis treatment in European and Canadian populations: a 6-month interim analysis of the 2-year, observational, prospective ACTION study.Factors influencing the use of tocilizumab as monotherapy in patients with rheumatoid arthritis in a real-life setting: results at 1 year of the ACT-SOLO study.Cardiac Tamponade as a Presenting Manifestation of Infliximab-Induced Lupus in Patient Treated for Crohn's Disease.Risk of invasive melanoma in patients with rheumatoid arthritis treated with biologics: results from a collaborative project of 11 European biologic registersImmunological risk factors for infection after immunosuppressive and biologic therapies.Biologics in oral medicine: ulcerative disorders.Biologics in oral medicine: Sjogren syndrome.Utilizing registries in systemic lupus erythematosus clinical research.CD22 and autoimmune disease.Biologic therapies in rheumatoid arthritis and the risk of opportunistic infections: a meta-analysis.anti-TNF agents as therapeutic choice in immune-mediated inflammatory diseases: focus on adalimumab.Comparison of characteristics of international and national databases for rheumatoid arthritis: a systematic literature review.Safety of subcutaneous versus intravenous tocilizumab in combination with traditional disease-modifying antirheumatic drugs in patients with rheumatoid arthritis.Safety of Anti-TNF Therapies in Immune-Mediated Inflammatory Diseases: Focus on Infections and Malignancy.Points to consider for reporting, screening for and preventing selected comorbidities in chronic inflammatory rheumatic diseases in daily practice: a EULAR initiative.Monotherapy with biologic disease-modifying anti-rheumatic drugs in rheumatoid arthritis.Predictive risk factors of serious infections in patients with rheumatoid arthritis treated with abatacept in common practice: results from the Orencia and Rheumatoid Arthritis (ORA) registry.[Safe use of biological therapies for the treatment of rheumatoid arthritis and spondyloarthritides].Risk of tuberculosis, serious infection and lymphoma with disease-modifying biologic drugs in rheumatoid arthritis patients in Taiwan.Risk of infection in patients with spondyloarthritis and ankylosing spondylitis receiving antitumor necrosis factor therapy: A meta-analysis of randomized controlled trials.Analysis of infections and all-cause mortality in phase II, phase III, and long-term extension studies of tofacitinib in patients with rheumatoid arthritis.
P2860
Q26852235-02340AEB-87BF-4DC3-B6FD-F99EED5B902EQ30234303-6455F137-4A3F-4434-9AFD-C072EC679888Q30645118-6F8E8B1B-716A-42C1-A82A-9C4D296000BEQ30725001-3923141A-DDE6-415D-B553-52F49E3810F2Q30891297-86DEB522-80D1-4D34-A142-4A47FEC1B354Q30940329-5CC3B0A5-39FB-415E-A754-0E7D7D94CA25Q31012265-4EBC8A9F-AB99-4DD6-B490-591053F7D08CQ31152756-4ECE189B-B1B3-4677-8B8D-6A6FF2C62D66Q33725553-14C43B35-D16E-44C0-A7DE-9200AB69A137Q33809045-5980ABA7-0C20-41AD-9784-94E200FB4DB8Q34818996-ABBBD6B8-F459-4D3A-AAC3-097A34C4D906Q35754240-B4101073-5129-415A-B451-0654873EA338Q35974381-32C25D9C-1237-4FED-B2E7-BCFD201E9868Q36036975-4C773A04-42AD-48A5-A490-3EC8EF4A2AE6Q36281132-B4DF3BC6-4955-401A-AF6A-68B9DA7AA9BEQ36639017-4A1CC6DD-4CAD-453F-A099-A0070F37F8E3Q36942901-FB4E7162-FD37-4740-B62D-B208EC156B39Q36942975-97D564D2-8137-4D25-8372-521D9996831DQ37358271-24FAD400-4A7E-4CBC-A9C0-72664D5697CFQ37501529-D1E1034A-6451-4059-988E-8D0594E73A30Q37587403-C8B13B1B-D6C5-4DAA-BBE5-AADF5C33AA2CQ37593973-20B8385B-D897-4983-AFC3-10EAD7C1DBDDQ37616987-4D51D381-38F9-4127-B562-591B3DE07A33Q37866813-794A7089-2A6D-4450-979C-9023A7232F54Q37999475-04953385-70FA-4DD9-8303-26E2A7425F01Q38002156-C63C18DB-49F0-4E4B-8F30-F66688852200Q38011226-36430082-239C-4D34-BA8D-3E2BFB06AE05Q38053491-3E28EB3F-1BC9-407B-A7F7-DE3A93F4EBF4Q38197448-E5BCE5FE-1D24-42B5-A83F-8FDC7D11497DQ38207759-B81AAE27-FC1B-47DF-8B8E-D91DA3697618Q38217664-629FC089-FDE0-4455-A928-CB75232A9EACQ38305522-0473A86C-CE30-4B43-850C-E3120A1851C8Q38611360-0A6D376E-A320-4C35-8DC5-223C9DDDB658Q38777496-9A7D64FA-166A-4A37-B7C2-4611F33383BDQ38828876-17B3ED85-30BD-4B3A-B883-B2CD6FCC7166Q40864639-99A7F978-BD11-4ACC-AD9D-9C5845C950E2Q41176187-624178C5-39C7-4A48-BFB6-C9ED502862D3Q41605548-F935CDA1-2177-4D0D-89F9-E96263605A6DQ42376342-0E939BDC-4949-45B6-9916-E35DB75D1A38Q44518151-7727FD27-7792-490A-92CC-F428963E512E
P2860
Registries in rheumatoid arthritis and autoimmune diseases: data from the French registries.
description
2011 nî lūn-bûn
@nan
2011 թուականի Յունուարին հրատարակուած գիտական յօդուած
@hyw
2011 թվականի հունվարին հրատարակված գիտական հոդված
@hy
2011年の論文
@ja
2011年論文
@yue
2011年論文
@zh-hant
2011年論文
@zh-hk
2011年論文
@zh-mo
2011年論文
@zh-tw
2011年论文
@wuu
name
Registries in rheumatoid arthr ...... ta from the French registries.
@ast
Registries in rheumatoid arthr ...... ta from the French registries.
@en
type
label
Registries in rheumatoid arthr ...... ta from the French registries.
@ast
Registries in rheumatoid arthr ...... ta from the French registries.
@en
prefLabel
Registries in rheumatoid arthr ...... ta from the French registries.
@ast
Registries in rheumatoid arthr ...... ta from the French registries.
@en
P356
P1433
P1476
Registries in rheumatoid arthr ...... ta from the French registries.
@en
P2093
Bernard Combe
Xavier Mariette
P304
P356
10.1093/RHEUMATOLOGY/KEQ368
P577
2011-01-01T00:00:00Z